Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity.
Silicon, in the form of sodium silicate (Na2SiO3), adsorbed onto bovine serum albumin (BSA)-precoated plates served as the solid-phase antigen in an enzyme immunoassay to detect silicate-reactive antibodies in the plasma of 40 symptomatic women with silicone breast implants, 91 asymptomatic women with silicone breast implants, 50 healthy control women, and 52 women with rheumatic diseases and without silicone breast implants, Silicate-reactive antibodies of immunoglobulin G (IgG) or IgM isotypes were detected in the plasma of 30% (12 of 40) of the symptomatic women with silicone breast implants; 9% (8 of 91) of the asymptomatic women with silicone breast implants; 5% (1 of 20) of the women without implants who had systemic lupus erythematosus; and 0% (0 of 32) of the women without implants who had either Sjögren syndrome, scleroderma, or rheumatoid arthritis. Only 2% (1 of 50) of the sera from the healthy control women contained silicate-reactive antibodies. Preincubation of sera with silicate and eight other metal compounds (including SiO2) demonstrated that the IgG and IgM antibodies bound specifically to silicate, because preincubation with Na2SiO3 inhibited more than 90% of the activity, whereas CrO3, Li2SO4, MgSO4, NiSO4, HgCl2, ZrOCl2, BeSO4, and SiO2 failed to inhibit the IgG or IgM antibody binding to the silicate-BSA plates. Furthermore, the F(ab')2 portion and not the Fc portion of the silicate-reactive IgG was reactive with BSA-bound silicate in the enzyme immunoassay. The assay for silicate-reactive antibodies was quantified by assigning arbitrary units to a standard curve composed of serial twofold dilutions of high-positive (ten times higher than the cutoff) silicate antibody sera. This novel assay is a useful method for detecting and quantifying humoral immune response to silicate.
Shen
G Q
GQ
Specialty Laboratories, Inc., Santa Monica, California 90404-3900, USA.
Ojo-Amaize
E A
EA
Agopian
M S
MS
Peter
J B
JB
D000917:Antibody Formation / Q000187:drug effects*; D000941:Antigens / Q000097:blood / Q000276:immunology; D001327:Autoimmune Diseases / Q000097:blood; D018427:Breast Implants / Q000009:adverse effects*; D002352:Carrier Proteins / Q000097:blood; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000032:analysis*; D007118:Immunoassay / Q000379:methods* / Q000592:standards; D007140:Immunoglobulin Fab Fragments / Q000502:physiology; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood; D015588:Observer Variation; D012016:Reference Values; D015203:Reproducibility of Results; D012710:Serum Albumin, Bovine / Q000378:metabolism; D017640:Silicates / Q000276:immunology* / Q000592:standards; D012828:Silicones / Q000009:adverse effects*; D017186:Titrimetry
D000941:Antigens; D002352:Carrier Proteins; D007106:Immune Sera; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D017640:Silicates; D012828:Silicones; D012710:Serum Albumin, Bovine